Phase 2 Liver Cancer Trial, Recruiting NCT06420440 Sponsor: Chen Xiaoping Condition: Liver Cancer
Back to Liver Cancer

Phase 2 Liver Cancer Trial, Recruiting

NCT06420440
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 75 years old
  • You have not previously received any treatment (local or systemic) for liver cancer
  • Your liver function is at an acceptable level, based on a scoring system called Child-Pugh (score of 7 or below — confirm with trial site)
  • You are able to carry out daily activities with little or no limitation (based on a performance scale called ECOG PS 0–1 — confirm with trial site)
  • You do not have serious diseases affecting your heart, lungs, brain, or kidneys
  • Scans show that your liver tumor could be surgically removed, but carries a high risk of coming back, and the cancer has not spread to distant parts of the body (confirm with trial site)
  • Your liver cancer diagnosis has been confirmed by a tissue sample (biopsy)
  • A specialist computer model — using information from your tissue sample, scans, and genetic data — suggests you may benefit from the combination treatment used in this trial (confirm with trial site)

Who may not be able to join:

  • Women who are pregnant or breastfeeding
  • People who have a condition that may prevent the study medication from being properly absorbed or processed by the body (for example, severe vomiting, long-term diarrhea, or bowel blockage)
  • People who have had bleeding in their stomach or digestive system in the past 4 weeks, or who are considered at high risk of such bleeding
  • People who currently have an active infection
  • People with other significant health or test result abnormalities that could affect safety (confirm with trial site)
  • People who are unable to follow the trial's treatment schedule or attend follow-up appointments as required

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 2 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Chen Xiaoping
Registry
ClinicalTrials.gov
Start date
1 June 2024
Est. completion
31 May 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Median event-free survival (EFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov